Jasper Therapeutics, Inc.

NASDAQ (USD): Jasper Therapeutics, Inc. (JSPR)

Last Price

22.50

Today's Change

+0.79 (3.63%)

Day's Change

21.70 - 22.84

Trading Volume

116,563

Profile
JSPR

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Ronald A. Martell Mr. Ronald A. Martell

Full Time Employees:  45 45

IPO Date:  2020-01-10 2020-01-10

CIK:  0001788028 0001788028

ISIN:  US4718712023 US4718712023

CUSIP:  471871103 471871103

Beta:  2.20 2.20

Last Dividend:  0.00 0.00

Dcf Diff:  14.61 14.61

Dcf:  8.06 8.06

Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Address

2200 Bridge Pkwy,
Redwood City, CA 94065, US

650 549 1400

http://jaspertherapeutics.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment